BackTable / Urology / Podcast / Episode #10

Management of Locally Advanced Kidney Cancer

with Dr. Vitaly Margulis and Dr. Aditya Bagrodia

Dr. Aditya Bagrodia interviews Dr. Vitaly Margulis, professor of urology at UT Southwestern Medical Center, about locally advanced kidney cancer. They discuss various topics including classification of locally advanced kidney cancers, various imaging modalities for staging cancer, special considerations for tumor-thrombus formation, targeted therapy vs. checkpoint inhibitors, and robotic vs. open nephrectomies.

Management of Locally Advanced Kidney Cancer with Dr. Vitaly Margulis and Dr. Aditya Bagrodia on the BackTable Urology Podcast)
Ep 10 Management of Locally Advanced Kidney Cancer with Dr. Vitaly Margulis and Dr. Aditya Bagrodia
00:00 / 01:04

BackTable, LLC (Producer). (2021, July 1). Ep. 10 – Management of Locally Advanced Kidney Cancer [Audio podcast]. Retrieved from https://www.backtable.com

Earn CME

Reflect on how this Podcast applies to your day-to-day and earn AMA PRA Category 1 CMEs.
Follow the button below to get started with CMEfy.

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Vitaly Margulis discusses Management of Locally Advanced Kidney Cancer on the BackTable 10 Podcast

Dr. Vitaly Margulis

Dr. Vitaly Margulis is a Professor of Urologic Oncology at UT Southwestern Medical Center in Dallas, Texas.

Dr. Aditya Bagrodia discusses Management of Locally Advanced Kidney Cancer on the BackTable 10 Podcast

Dr. Aditya Bagrodia

Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.

Show Notes

In this episode of BackTable Urology, Dr. Vitaly Margulis, professor of urology at UT Southwestern Medical Center, joins Dr. Aditya Bagrodia in a thorough discussion about locally advanced kidney cancer.

First, the doctors classify locally advanced kidney cancers and discuss various imaging modalities used in staging this type of cancer. Dr. Margulis uses MRI, chest CT, and direct radiographic imaging to visualize patient anatomy. He notes that PET scans have a very limited role in staging.

Although extensive metastasis is not present in locally advanced kidney cancer, small metastases--such as pulmonary nodules and small pancreatic/liver metastases--may be present. In these cases, Dr. Margulis emphasizes the importance of collaboration with interventional radiologists to choose the optimal site to biopsy, as biopsy can trigger a hemorrhage of the primary tumor site. He notes that the easiest site to access may not be the best site to biopsy.

Next, Dr. Margulis discusses pros and cons of the two broad types of general systemic therapy: targeted therapy and checkpoint inhibitors. In his clinical practice, he uses a combination of both therapies and continues until the maximal response is reached. He notes that pseudoprogression, or the process of the tumor initially swelling and then shrinking, may be possible.

Furthermore, Dr. Margulis discusses general surgical considerations for other types of locally advanced kidney cancers, such as the necessity of performing a lymph node dissection and whether to take an open or robotic surgical approach. Dr. Margulis also shares special surgical considerations in locally advanced kidney cancers that cause the formation of a tumor-thrombus. He first categorizes these thrombi into two categories--bland thrombus vs. pulmonary emboli--and explains how they can make surgical intervention more complicated. When operating on these cases, he always has a multidisciplinary team with echocardiogram capabilities.

Finally, he shares his clinical opinions about neoadjuvant and adjuvant therapies, two new approaches to locally advanced kidney cancer. He notes that neoadjuvant therapy may be useful, as it can shrink the primary tumor pre-operatively, but he does not use post-operative adjuvant therapy because of its inability to increase survival rates. However, he notes that using checkpoint inhibitors in an adjuvant setting may improve outcomes.

Transcript Preview

[Dr. Aditya Bagrodia]
I think there's so much that's exciting and coming through the pipeline, novel agents, theranostics, improved imaging, selection of patients that may or may not have had a complete response to checkpoint inhibitor, local therapy of metastasis, the role of cytoreductive nephrectomy. I think we're really on the cusp of a very, very exciting time in the management of kidney cancer.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Earn CME When You Listen to BackTable CMEfy

Up Next

Adjuvant Therapy for Advanced Kidney Cancer: Who, What, When with Dr. Rana McKay and Dr. Karim Bensalah on the BackTable Urology Podcast)
Management of Small Renal Masses with Dr. Phil Pierorazio on the BackTable Urology Podcast)
Management of Testicular Cancer with Dr. Aditya Bagrodia and Dr. Jose Silva on the BackTable Urology Podcast)
Management of Bladder Cancer with Dr. Aditya Bagrodia and Dr. Jose Silva on the BackTable Urology Podcast)
Breaking Down Upper Tract Malignancy with Dr. Katie Murray on the BackTable Urology Podcast)

Articles

Renal cell carcinoma with tumor thrombus in the interior vena cava

Tumor Thrombus & Budd Chiari Syndrome in Kidney Cancer

Kidney cancer surgery, specifically, a nephrectomy

Kidney Cancer Surgery: Nephrectomy, Lymph Node Dissection, When & Why

Topics

Budd Chiari Syndrome Condition Overview
Kidney Biopsy Procedure Prep
Kidney Cancer Condition Overview
Lymph Node Dissection Procedure Prep
Nephrectomy Procedure Prep

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.